Impact of sarcopenia in patients with advanced or recurrent colorectal cancer treated with regorafenib.

Yasushi MurachiDaisuke SakaiJun KosekiChiaki InagakiNaohiro NishidaToshifumi YamaguchiTaroh Satoh

Published in: International journal of clinical oncology (2020)

Sarcopenia was a predictive marker of negative outcome for patients with advanced or recurrent colorectal cancer treated with regorafenib. Screening for sarcopenia can be used to identify patients more likely to benefit from regorafenib in routine clinical practice.

Keyphrases

clinical practice
newly diagnosed
skeletal muscle
metastatic colorectal cancer
end stage renal disease
ejection fraction
community dwelling
prognostic factors
patient reported outcomes